Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Olema Pharmaceuticals, Inc. (OLMA)
|
Add to portfolio |
|
|
|
| Price: |
$8.88
| | Metrics |
| OS: |
41.4
|
M
| |
-60
|
% ROE
|
| Market cap: |
$367
|
M
| |
-78
|
% ROIC
|
|
Net cash:
|
$167
|
M
| |
$4.05
|
per share
|
|
EV:
|
$200
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($101)
|
M
| |
|
|
|
EBIT
|
($102)
|
M
| |
|
|
| EPS |
($2.42)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | |
| Research and development | 82.3 | 51.1 | 13.7 | 3.9 | |
| General and administrative | 24.7 | 20.4 | 7.8 | 0.4 | |
| EBIT | -107.0 | -71.5 | -21.5 | -4.3 | |
| Pre-tax income | -104.8 | -71.1 | -22.1 | -4.3 | |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | |
| Tax rate | | 0.0% | 0.0% | 0.0% | |
| Net income | -104.8 | -71.1 | -24.0 | -4.3 | |
| |
| Diluted EPS | ($2.62) | ($1.80) | ($3.42) | ($1.66) | |
| Shares outstanding (diluted) | 40.0 | 39.5 | 7.0 | 2.6 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|